• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

In­sid­er trad­ing scam spurred by $11.2B Gilead deal earns a stretch in prison

8 years ago
Pharma

No­var­tis ties a new round of biosim­i­lar de­vel­op­ment pro­grams to a part­ner­ship deal with In­di­a's Bio­con

8 years ago
R&D
Pharma

Tired of be­ing gouged for old, cheap ther­a­pies, a con­sor­tium of hos­pi­tals is go­ing in­to the drug busi­ness — NYT

8 years ago
Pharma

With $58M in hand, the start­up team at Pan­dion sets their sights on a next-gen ap­proach to im­munol­o­gy

8 years ago
Financing
Startups

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

8 years ago
Financing
Special

With Pfiz­er in hot pur­suit, J&J los­es a crit­i­cal patent fight as it scram­bles for a new prostate can­cer drug OK

8 years ago
Pharma

France's Owkin rais­es $11M Se­ries A for AI-aid­ed drug de­vel­op­ment; As­traZeneca ex­pands dis­cov­ery deal with X-Chem

8 years ago
News Briefing

FDA and Pen­ta­gon forge break­through des­ig­na­tion agree­ment

8 years ago
Pharma

Mer­ck KGaA taps UK can­cer re­search or­ga­ni­za­tions to feed pipeline

8 years ago
R&D
Pharma

Af­ter a bruis­ing year, Aeter­na Zen­taris inks a $24M up­front US pact for growth hor­mone as­set

8 years ago
Pharma

Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

8 years ago
R&D
Pharma

Is Juno worth a $10B-$12B buy­out price? An­a­lysts see megabucks deal in the mak­ing on re­port­ed Cel­gene talks

8 years ago
Deals

FDA com­mis­sion­er Scott Got­tlieb just broke a pub­lic promise on pub­lish­ing CRLs — and yes, it mat­ters

8 years ago
Bioregnum
Pharma

AveX­is wants $400M more for promis­ing SMA gene ther­a­py; Shang­Phar­ma part­ners with Ic­ahn School of Med­i­cine at Mount ...

8 years ago
News Briefing

Chi­na biotech uni­corn In­novent in talks on $200M IPO and new fund­ing — re­port

8 years ago
Financing

De­vel­op­ers are lay­ing the foun­da­tion for a new biotech com­plex in Cal­i­for­nia

8 years ago
Pharma

Ger­man drug­mak­er files $21.6M IPO for skin can­cer drug

8 years ago
Financing

Eiger Bio scraps a mid-stage pro­gram af­ter re­searchers record a clear flop in PAH, shares skid low­er

8 years ago
R&D

Mer­ck’s Keytru­da com­bo wows again, ac­ing PhI­II over­all sur­vival goal for lung can­cer ear­ly

8 years ago
R&D

Pre­clin­i­cal study finds Gen­mab may hold the key to a next-gen triple fol­lowup to MEK/BRAF com­bos

8 years ago
Discovery

Google backs $27M launch round for Holy Grail R&D work on two tar­gets: a can­cer vac­cine and a uni­ver­sal flu jab

8 years ago
Financing
Startups

Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

8 years ago
Pharma

Video: How many PD-1/L1 drugs do we need? Where is im­munother­a­py head­ed? Watch Jay Brad­ner, Hervé Hop­penot, Ellen ...

8 years ago
Special
Pharma

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

8 years ago
News Briefing
First page Previous page 1065106610671068106910701071 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Confirm Profile

Endpoints News